{"id":"NCT01003184","sponsor":"AstraZeneca","briefTitle":"Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes","officialTitle":"Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulphonylurea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-07","completion":"2011-12","firstPosted":"2009-10-28","resultsPosted":"2012-12-18","lastUpdate":"2015-04-07"},"enrollment":222,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"exenatide once weekly","otherNames":[]},{"type":"DRUG","name":"insulin detemir","otherNames":["Levemir"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the effects of exenatide once weekly (QW) and insulin detemir with respect to glycemic control, body weight, lipids, safety, tolerability, and patient reported outcomes.","primaryOutcome":{"measure":"Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26)","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Exenatide Once Weekly","deltaMin":44.1,"sd":null},{"arm":"Insulin Detemir","deltaMin":11.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":34,"countries":["Ireland","United Kingdom"]},"refs":{"pmids":["32306296"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":111},"commonTop":["Nausea","Nasopharyngitis","Headache","Diarrhoea","Vomiting"]}}